Seasonique is a contraceptive drug owned by Teva Branded Pharm. It contains the active ingredients Ethinyl Estradiol and Levonorgestrel. It was first authorized for market use on 25 May 2006.
The generic version of Seasonique is projected to be released after 05 December 2028. This is determined by the expiration of the last patent held by Teva Branded Pharm, specifically patent US7855190, which expires on that date.
Seasonique is primarily used for the prevention of pregnancy in women who choose to use oral contraceptives as their method of contraception. It works by utilizing its active ingredients, Ethinyl Estradiol and Levonorgestrel, to inhibit ovulation and thus prevent pregnancy.
Seasonique has a total of 4 drug patents, two of which have already expired. The remaining patents, US7320969 and US7855190, are due to expire on 30 January 2024 and 05 December 2028, respectively. It is the latter that determines the earliest possible date for when the Seasonique generic can become available. Below are the details of the patent: